Relief Therapeutics holds FDA and EU orphan drug designations for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a US patent[1] for Aviptadil and proprietary manufacturing processes for its synthesis. “In a previous trial of VIP for ARDS in patients ...
Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trialAviptadilVIPCOVID-19ARDSSARS-CoV-2ClinicalTrials.gov, NCT04536350 . Registered 02 September 2020....
Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)Vasoactive Intestinal Peptide AcetateSARS-CoV-2SARS-CoVSARSCoVSARS coronavirusSarcoidosisSarcoidRespiratory FailureRespiratory Distress SyndromePulmonary FibrosisLung InjuryInhibitorinhibitCorona VirusBronchospasmAviptadil AcetateAviptadilARDSALIACERel...
as well as in a recently published phase I trial in the treatment of ARDS [43,48–50]. Aviptadil has been given Orphan Drug Designation in the European Union and the USA for the treatment of ARDS and the inhaled
RLF-100™目前正在进行SARS-CoV-2病毒(COVID-19)相关的急性呼吸窘迫综合征(ARDS)和急性肺损伤(ALI)的临床试验。以及计划开发用于轻症COVID-19和其他急性和慢性肺部疾病,包括肺结节病。 关于结节病 结节病是一种罕见的疾病,其炎症过程涉及肺泡(气囊)、小支气管和小血管。随着疾病的进展,受累组织中会出现小肿块或...